Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial.

Abstract

BACKGROUND Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of the gastrointestinal tract. They are defined immunohistologically as KIT positive tumours. The only effective treatment for malignant GIST was surgery until 2000. Imatinib mesylate (STI571, Glivec) has shown substantial anticancer activity in patients with… (More)

Topics

Cite this paper

@article{Prenen2006ImatinibFT, title={Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial.}, author={Hans Prenen and Herlinde Dumez and Cristiana Stefan and Ann Hoeben and C. Wouters and Marie-Anne van Lierde and Raf Sciot and Allan T. van Oosterom and Marc Peeters and Marc Polus and Lionel Duck and Thierry Gil and Patrick Sch{\"o}ffski}, journal={Acta gastro-enterologica Belgica}, year={2006}, volume={69 4}, pages={367-71} }